GLI1 and neoplasm: In agreement with the role of Hh signaling in tumor development, a variety of drugs have been developed in the recent years to block this signaling pathway in cancer cells including Hh antagonist SANTs1–4, Gli inhibitor GANT-61, and smoothened inhibitor NVP-LDE-225 [18–20].